Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2017-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The BCN02-Romi study aims to evaluate a combined "kick and kill" strategy using the most immunogenic candidate vaccine available so far (HIVconsv) with the strongest latency reversal agent available at present time (romidepsin) in a cohort of early-treated HIV positive individuals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

NCT03041012

Hiv

COMPLETED PHASE2

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

NCT02415595

Infection, Human Immunodeficiency Virus

TERMINATED PHASE2

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068

HIV-1-infection

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

NCT00460746

HIV

COMPLETED PHASE3

A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART

NCT01571466

HIV Infection

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The combined use of therapeutic vaccination and specific drugs that can reactivate latent virus from the reservoir (Kick and kill strategies) hold the promise to achieve functional cure and viral eradication of HIV infection. The present project consists of a proof-of-concept clinical trial in a cohort of 24 early treated HIV-1 infected individuals rolled-over from the BCN01 vaccine clinical trial in which participants received the most immunogenic vaccines tested to date, ChAd and modified vaccinia Ankara (MVA).HIVconsv vaccines. All individuals will be given a booster immunization with MVA.HIVconsv in combination with romidepsin (RMD), a potent histone deacetylation inhibitor (HDACi) and will later undergo a monitored antiretroviral pause. HIVconsv vaccines have specifically been designed to stimulate a broad and potent cytotoxic T cell (CTL) response towards the most conserved viral regions of the HIV-1 proteome, which have recently been suggested to have a crucial role when targeting HIV variants harboured in the latent reservoir with mutations to escape T-cell immune responses. The study includes the development of a population pharmacokinetic/pharmacodynamic (PK/PD) substudy to analyse the in vivo effects of RMD in the induction of HIV expression in resting cells, deeply investigate any unintended effect on the CTL function as well as predict the relationship between RMD exposure and such effects. The investigators' results will allow investigators to optimize RMD dosing, to evaluate the clinical efficacy of this eradication strategy after the cART interruption and to identify better correlates of control of rebound viremia after cessation of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MVA.HIVconsv plus romidepsin

Group Type EXPERIMENTAL

MVA.HIVconsv vaccine

Intervention Type DRUG

Dose: 2x10e8 pfu, Interval: weeks 0 and 9.

Romidepsin

Intervention Type DRUG

Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MVA.HIVconsv vaccine

Dose: 2x10e8 pfu, Interval: weeks 0 and 9.

Intervention Type DRUG

Romidepsin

Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject included in ChAd-MVA.HIVconsv\_BCN01 study with complete follow-up and included in BCN01-RO extension study.
2. Optimal virological suppression for at least 3 years.cop/ml).
3. Being on a non-boosted integrase-inhibitor based regimen (raltegravir or dolutegravir) for at least 4 weeks at screening visit.
4. Haematological and biochemical laboratory parameters as follows:

* Haemoglobin \> 10g/dl
* Platelets \> 100.000/dl
* Alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)
* Creatinine ≤ 1.3 x ULN
5. CD4 T cell count ≥500 cells/mm3

Exclusion Criteria

1. Positive pregnancy test.
2. Presence of resistance drug mutations in the screening genotype
3. History of autoimmune disease other than HIV-related auto-immune disease.
4. Treatment for cancer or lymphoproliferative disease within 1 year of study entry
5. Any other prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study
6. Current or recent use (within last 3 months) of interferon or systemic corticosteroids or other immunosuppressive agents

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No